Active Ingredient(s): Risdiplam
FDA Approved: * August 7, 2020
Pharm Company: * GENENTECH INC
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Evrysdi Overview

Risdiplam, sold under the brand name Evrysdi, is a medication used to treat spinal muscular atrophy (SMA)[2][3] and the first oral medication approved to treat this disease.[2][3] Risdiplam is a survival of motor neuron 2-directed RNA splicing modifier.[2][1][4] In clinical trials, the most common adverse events included fever, diarrhea, rash, ulcers of the mouth area, joint pain (a...

Read more Evrysdi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Risdiplam

Recent Evrysdi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • For Solution: 0.75mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Evrysdi: (1 result)

Sorted by National Drug Code
  • 50242-175 Evrysdi .75 mg/ml Oral Powder, for Solution by Genentech Inc.

Other drugs which contain Risdiplam or a similar ingredient: (1 result)